BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19898259)

  • 1. Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.
    Takahashi H; Arimura Y; Yamashita K; Okahara S; Tanuma T; Kodaira J; Hokari K; Tsukagoshi H; Shinomura Y; Hosokawa M
    J Thorac Oncol; 2010 Jan; 5(1):122-8. PubMed ID: 19898259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
    Yamasaki M; Miyata H; Tanaka K; Shiraishi O; Motoori M; Peng YF; Yasuda T; Yano M; Shiozaki H; Mori M; Doki Y
    Oncology; 2011; 80(5-6):307-13. PubMed ID: 21778771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
    Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
    J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
    Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
    Honda M; Miura A; Izumi Y; Kato T; Ryotokuji T; Monma K; Fujiwara J; Egashira H; Nemoto T
    Dis Esophagus; 2010 Nov; 23(8):641-5. PubMed ID: 20545978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
    Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
    Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
    Tebbutt NC; Price TJ; Ferraro DA; Wong N; Veillard AS; Hall M; Sjoquist KM; Pavlakis N; Strickland A; Varma SC; Cooray P; Young R; Underhill C; Shannon JA; Ganju V; Gebski V
    Br J Cancer; 2016 Mar; 114(5):505-9. PubMed ID: 26867157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
    Guo JF; Zhang B; Wu F; Wang B; Xing H; Zhu GY; Nie XY; Peng J
    Chin J Cancer; 2010 Mar; 29(3):321-4. PubMed ID: 20193118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus.
    Zhang X; Shen L; Li J; Li Y; Li J; Jin M
    Am J Clin Oncol; 2008 Feb; 31(1):29-33. PubMed ID: 18376224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
    Tanaka T; Fujita H; Sueyoshi S; Tanaka Y; Sasahara H; Mori N; Nagano T; Yamana H; Shirouzu K
    Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
    Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
    N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
    Zhang XD; Shen L; Li J; Li Y; Li J; Zhang XT; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):474-7. PubMed ID: 17974288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
    Miyazaki T; Ojima H; Fukuchi M; Sakai M; Sohda M; Tanaka N; Suzuki S; Ieta K; Saito K; Sano A; Yokobori T; Inose T; Nakajima M; Kato H; Kuwano H
    Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
    Tanaka Y; Yoshida K; Yamada A; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K; Miyazaki T
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1143-52. PubMed ID: 26896963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.
    Fujii M; Tomita K; Nishijima W; Tsukuda M; Hasegawa Y; Ishitoya J; Yamane H; Homma A; Tomita T
    Jpn J Clin Oncol; 2010 Mar; 40(3):214-21. PubMed ID: 19934112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403).
    Tamura S; Imano M; Takiuchi H; Kobayashi K; Imamoto H; Miki H; Goto Y; Aoki T; Peng YF; Tsujinaka T; Furukawa H;
    Anticancer Res; 2012 Apr; 32(4):1403-8. PubMed ID: 22493377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.